Guichuang Tonqiao (02190.HK) Further Acquires 11% Stake in German Optimed

Gelonghui, March 17 — Guichuang Tongqiao (02190.HK) announced that it has acquired a 49% stake in Optimed Holding, Germany. On March 17, 2026, the company issued a notice to exercise the subscription option to further acquire an 11% stake in the target company. After exercising the option, the company will need to acquire the remaining 40% of the target company’s shares in the first half of 2028 (“Further Acquisition”). Following the exercise of the option, the target company will become a subsidiary of the company, and its financial performance will be consolidated into the company’s financial statements.

The target company is a limited liability company incorporated under German law. As of the date of this announcement, the target company is wholly owned by the seller. The target group mainly engages in the development, manufacturing, and distribution of medical technology products, instruments, and solutions. Within the group, the wholly owned subsidiary Optimed Medizinische Instrumente GmbH (“Optimed”) is its main operating subsidiary. Headquartered in Eitlingen, Germany, Optimed focuses on the research, manufacturing, and global distribution of high-quality minimally invasive vascular and urological surgical instruments. Optimed offers the most comprehensive product portfolio in the peripheral venous stent market, including devices for iliac-femoral veins, iliac artery bifurcation, inferior vena cava, and aortic applications.

The board believes that exercising the option and the further acquisition will bring the following benefits to the company:

1. A milestone marking the company’s long-term commitment to global expansion

The acquisition is a key milestone in the company’s long-term strategy to enter European and global markets. By integrating these assets, the company will accelerate its international strategic deployment, diversify its product portfolio, and expand its global distribution network, significantly enhancing its competitive position and influence on the international stage.

2. Building an integrated global commercialization platform to accelerate the worldwide application of innovative vascular solutions

The integration of the sales networks of the company and Optimed will accelerate the global deployment of innovative vascular solutions. With a broader and more diverse product portfolio, the company is well-positioned to expand into markets outside mainland China. A key element of this strategy is leveraging Optimimed’s strong partnerships with European medical experts to accelerate clinical trials and promote successful product launches and marketing.

3. Achieving synergies in manufacturing and operations between Germany and China

This transaction will generate significant manufacturing and operational synergies in Germany and China. By integrating advanced production capabilities, the company will continue to improve overall product quality and operational efficiency. The company will also continue to leverage the strong brand recognition of the target in Europe while strategically expanding its manufacturing capacity in Germany to ensure a reliable, efficient supply for Europe and other key international markets.

4. Fully unleashing the Group’s efficient R&D capabilities

The company’s integrated global commercialization platform will empower and fully leverage the Group’s efficient R&D capabilities. By extending the company’s innovations from China to the global market, the company is committed to continuously providing cutting-edge, high-quality medical solutions for patients and healthcare professionals worldwide.